Jacobs inks Boehringer Ingelheim contract
Ingelheim to provide technical and construction services for its
new bulk active pharmaceutical ingredient (API) facility being
built in Petersburg, Virginia, US.
Under the deal, Jacobs will provide the German-based firm with preliminary and detail engineering/design, subcontract administration, and construction management services.
Financial terms of the deal were not disclosed.
Boehringer Ingelheim has been progressively undertaking improvements and API capacity expansion at its Petersburg site and this is the third time the firm has used Jacobs' services on the project.
"This project has been under development for over six years and we are delighted to continue our working relationship with Boehringer Ingelheim," said Jacobs Executive Vice President George Kunberger.
"Our significant pharmaceuticals experience will help Boehringer Ingelheim meet their new product manufacturing and speed to market objectives."
In June, Jacobs was also chosen to upgrade and expand GlaxoSmithKline's (GSK) manufacturing capability at its Irish plant, as well as develop a new biological manufacturing facility for US firm Northfield Laboratories.
